BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a focus on oncology and neurology. “UC San Diego is a leading research […]

A Letter to Our Shareholders from CEO Neil Kumar

Dear Shareholders, We are living in extraordinary times, marked by extraordinary human suffering. The COVID-19 pandemic is impacting all people and industries. We salute the brave physicians, nurses, first responders, and medical staff who are working across the globe to care for patients. In the face of these unprecedented challenges, we have been awed by […]

An Open Letter to Patients and Their Families from BridgeBio Pharma CEO Neil Kumar

The rapid spread of COVID-19 globally has led to tremendous disruption in the health care industry. We are actively assessing the impact the virus will have on our work at BridgeBio, including the timing of our clinical trials. We are doing our absolute best to minimize any delays, but we know that right now health […]

BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

PALO ALTO, Calif. – March 4, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant […]

BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress

-Achieved multiple clinical and pre-clinical milestones across BridgeBio’s pipeline -Delivered pipeline expansion with addition of five new drug development and discovery programs; BridgeBio’s portfolio now includes more than 20 potential medicines -Ended quarter with $577.1 million in cash, cash equivalents and marketable securities SAN FRANCISCO, March 02, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: […]